Research Analysts Set Expectations for Agenus Q3 Earnings

Agenus Inc. (NASDAQ:AGEN) – Analysts at HC Wainwright raised their Q3 2026 earnings per share (EPS) estimates for Agenus in a research note issued to investors on Friday, August 7th. HC Wainwright analyst E. Bodnar now forecasts that the biotechnology company will post earnings per share of $0.05 for the quarter, up from their prior estimate of $0.03. HC Wainwright currently has a “Buy” rating and a $30.00 target price on the stock. The consensus estimate for Agenus’ current full-year earnings is ($0.20) per share. HC Wainwright also issued estimates for Agenus’ Q4 2026 earnings at $0.05 EPS, FY2026 earnings at ($0.15) EPS, FY2027 earnings at ($0.19) EPS, FY2028 earnings at ($0.49) EPS, FY2029 earnings at ($0.58) EPS and FY2030 earnings at ($0.31) EPS.

A number of other equities analysts also recently weighed in on AGEN. Wall Street Zen raised shares of Agenus from a “buy” rating to a “strong-buy” rating in a research note on Sunday. B. Riley Financial reissued a “buy” rating and set a $14.00 price target (up from $8.00) on shares of Agenus in a research note on Thursday, July 30th. Weiss Ratings raised shares of Agenus from a “sell (d)” rating to a “sell (d+)” rating in a report on Friday. Finally, Zacks Research cut shares of Agenus from a “strong-buy” rating to a “hold” rating in a research report on Monday, May 11th. Two equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $22.00.

Agenus Stock Up 0.6%

Shares of NASDAQ:AGEN opened at $7.00 on Tuesday. Agenus has a 12 month low of $2.71 and a 12 month high of $8.85. The company’s 50-day moving average price is $4.54 and its two-hundred day moving average price is $3.84. The firm has a market cap of $313.25 million, a P/E ratio of 2.71 and a beta of 1.40.

Agenus (NASDAQ:AGEN) last issued its quarterly earnings results on Monday, May 11th. The biotechnology company reported $1.02 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.10 by ($1.08). The company had revenue of $33.74 million for the quarter, compared to analyst estimates of $129.50 million. Agenus had a negative return on equity of 45.12% and a net margin of 69.33%.

Institutional Trading of Agenus

Institutional investors and hedge funds have recently modified their holdings of the stock. Quadrature Capital Ltd acquired a new stake in Agenus in the fourth quarter worth $54,000. Price T Rowe Associates Inc. MD bought a new stake in shares of Agenus in the 4th quarter valued at $77,000. LPL Financial LLC increased its position in shares of Agenus by 20.3% in the 4th quarter. LPL Financial LLC now owns 23,326 shares of the biotechnology company’s stock valued at $73,000 after buying an additional 3,943 shares in the last quarter. Sherbrooke Park Advisers LLC acquired a new stake in Agenus during the 3rd quarter worth $64,000. Finally, Squarepoint Ops LLC bought a new position in Agenus during the third quarter worth about $54,000. 61.46% of the stock is owned by institutional investors.

Agenus Company Profile

Agenus, Inc (NASDAQ:AGEN) is a clinical-stage immuno-oncology company headquartered in Lexington, Massachusetts. The company focuses on the discovery and development of therapies designed to modulate the immune system’s response to cancer. Leveraging proprietary platforms in checkpoint modulation, vaccine technology and adjuvant systems, Agenus aims to deliver combination regimens that enhance antitumor activity across a variety of solid tumors and hematological malignancies.

Agenus’ pipeline includes monoclonal antibodies targeting immune checkpoints, cytokine-based therapeutics and vaccine candidates built on its engineered heat shock protein (HSP) platform.